Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective study assessing the rates of relapse, severe relapse, and health care resource utilization following Covid-19 vaccination in Multiple Sclerosis patients treated and untreated with Ocrelizumab, Ofatumumab, Siponimod or Fingolimod

Next Previous
Search
Trial Profile

A retrospective study assessing the rates of relapse, severe relapse, and health care resource utilization following Covid-19 vaccination in Multiple Sclerosis patients treated and untreated with Ocrelizumab, Ofatumumab, Siponimod or Fingolimod

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Glatiramer acetate (Primary) ; Ocrelizumab (Primary) ; Ofatumumab (Primary) ; Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 28 Jun 2022 Results assessing rates of MS relapse and healthcare resource utilisation following COVID-19 vaccination presented at the 8th Congress of the European Academy of Neurology
    • 06 Apr 2022 New trial record
    • 26 Feb 2022 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top